Facebook
Twitter
LinkedIn
Forward
Empowering Progress in RRMM through Patient Simulations: Evidence, Sequencing, and Equity
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: Varied
Overview
In this immersive educational program, participants will expand their understanding of managing patients with Multiple Myeloma. This program utilizes the innovative AliveSim platform, offering real-life clinical case scenarios to work through in a low-stress environment with guidance from experts in the field of Oncology. Patient case scenarios created by our expert faculty will cover key oncology topics such as mechanism of action of new and emerging therapies for relapsed remitting multiple myeloma (RRMM), clinical evidence on utility and potential sequencing of new and emerging RRMM treatment approaches, disparities in RRMM and leveraging RRMM treatment advances to overcome treatment disparities. Interact with virtual patients and physicians as you practice managing Multiple Myeloma cancer with expert clinical mentoring.
Target Audience
This activity is designed to educate the MM care team including hematologists, oncologists, nurse practitioners, physician assistants, pharmacists, and nurse specialists.
Learning Objectives
- Describe the mechanism-of-action of new and emerging therapies for the treatment of relapsed remitting multiple myeloma (RRMM)
- Review clinical evidence on the utility and potential sequencing of new and emerging RRMM treatment approaches with or without planned transplant
- Evaluate disparities in RRMM care and overall survival rates relative to treatment setting and ethnicity, particularly black patients
- Leverage RRMM treatment advances to overcome treatment disparities and optimize patient outcomes
Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc
Faculty
Carrie Bellerive, BSN, BS, RN, BMTCN is a Cellular Therapy Nurse Coordinator at Huntsman Cancer Institute. Her expertise includes innovative process-driven change to expedite clinical decision-making and improve patient outcomes. She is passionate about data-driven care, incorporating informatics into ambulatory workflows in her current and prior positions as a myeloma nurse specialist.She completed a BSN at Texas Woman's University. She worked as an inpatient nurse in the Bone Marrow Transplant unit at Baylor University Medical Center in Dallas, TX, where she received the 2019 Baylor Nurse Data-Driven Award. She has her ANCC certification and remains an active Blood & Marrow Transplant Registered Nurse (BMTCN®).
Carrie is strongly committed to research, nursing education, and patient advocacy. She has collaborated on various research projects with the Nurse Leadership Board of the International Myeloma Foundation, presenting an oral abstract and two posters at the International Myeloma Society’s annual conference. Her passion for nursing education is evident through her active involvement in the Program Committee for the Intermountain Chapter of the Oncology Nursing Society (ICONS), where she helps plan and execute quarterly educational sessions for nurses.
During the Hem/Onc program transition from non-clinical to nurse coordinators, Carrie played a pivotal role as the first MM nurse to establish processes and training for incoming team members. Her dedication to mentoring is reflected in her frequent work as a preceptor, guiding and supporting new nurses.
Carrie's advocacy for patient care extends to end-of-life care, demonstrated by completing the ASPIRE Research Project, “Nursing Confidence for End-of-Life Care Utilizing C.A.R.E.S. Tool.” She strongly believes in the importance of patient education and satisfaction, having received multiple awards, including a Patient Advocate Award, for her exceptional efforts in these areas.
Joseph Mikhael, MD, MEd, FRCPC, FACP
Dr Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF) and Director of Myeloma research at the HonorHealth Research Institute. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations. Dr. Mikhael also serves as the Treasurer on the executive of the American Society of Hematology.
Dr Mikhael has published over 200 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr. Mikhael is deeply committed to health disparities in myeloma and leads the diversity efforts of the IMF, namely the M-Power project in the African American community. He is also the chair of the Diversity, Equity and Inclusion Council at TGen. Dr. Mikhael is heavily involved in training future researchers and mentors junior faculty worldwide. He also spends nearly 20% of his time in the third world developing collaborations in myeloma and finding ways to enhance access to novel agents.
Beth Faiman, PhD, RN, MSN, APN-BC, BMTCN, AOCN, BMTCN, FAAN, FAPO
Beth Faiman has become an exemplary leader in bringing critical knowledge of cancer nursing to clinical providers- locally, nationally, and internationally. She demonstrates enthusiasm for continuous learning by conducting innovative research and has demonstrated the importance of using and integrating new medical knowledge within nursing practices. Dr. Faiman received her Bachelor of Science in Nursing degree from Ursuline Academy (1996), a Master of Science in Nursing at Kent State University (2002), and a PhD in clinical research from Case Western Reserve University (2014).
Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic in Ohio, and a clinical member of the Case Comprehensive Cancer Center. Faiman has over 200 peer-reviewed publications and served as an investigator on over 75 clinical trials. She has edited several books and authored many chapters and papers, including Editor of the 3rd Edition of the Multiple Myeloma Textbook for Nurses (2021), and both Editions of the Blood and Marrow Certification Manual for Nurses (2017, 2023), by ONS publishing. She previously held appointments on the American Board of Internal Medicine Maintenance of Hematology Certification Committee and American Society of Hematology.
In 2023, Faiman was given the NP/PA Educator of Distinction Award in Multiple Myeloma and in 2022, Faiman was named the Top NP in Hematology/Oncology and inducted as an inaugural Fellow of Advanced Practice in Oncology (FAPO) awarded by the Advanced Practitioner Society for Hematology and Oncology. Faiman is a Distinguished Fellow in the American Academy of Nursing (FAAN) and current Editor-in-Chief of Journal of the Advanced Practitioner in Oncology. She remains an active author, presenter, and educator on the topics of plasma cell disorders, hematology, oncology and supportive cancer care.
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Copyright Statement
This CME simulation activity is licensed to Horizon. Copyright © 2024 Syandus Inc and Horizon. All rights reserved. No part of this simulation activity may be reproduced without written permission from Horizon and Syandus Inc.
Ms. Bellerive discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
Dr. Faiman discloses that she is on an advisory board for Bristol Myers Squibb, Janssen, Karyopharm, Pfizer and Sanofi.
Dr. Mikhael discloses that he is a consultant for Bristol Myers Squibb, Janssen and Sanofi as well as contracted research for Bristol Myers Squibb.
Available Credit
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above